Special Issue

Prognostic Factors in Urologic Cancers—Assessment and Integration into Clinical Care

Message from the Guest Editors

As urological oncology is constantly advancing and offering additional options for cancer care, it is becoming ever more demanding. Which therapy is the most effective for a specific condition and is especially the most effective for a specific patient in such a specific condition? Individual therapy guidance and management is required to obtain the care each patient requires; in short, personalized medicine is required. The key to such personalized medicine is the assessment and interpretation of risk factors defining the outcome of urological cancers and their integration into clinical management. Molecular markers, clinical parameters impacting surgical and medical therapy, histopathology, and socio-economic factors shape the outcome of this, but we need to understand much more. While there will be no such thing as an equation for uranological management, we should try to keep up the pace. We invite you to contribute original data, metaanalyses, and reviews which deal with prognostic factors in urological cancers to this Special Issue. Prof. Dr. Christian Thomas

Guest Editors

Prof. Dr. Maximilian Burger

Department of Urology, St. Josef Medical Center, University of Regensburg, Landshuterstraße 65, 93053 Regensburg, Germany

Prof. Dr. Christian Thomas

Department of Urology, Carl Gustav Carus University Dresden, 01307 Dresden, Germany

Deadline for manuscript submissions

closed (30 June 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/171539

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

